HGV agrees to divest its investment in Entourage Health Corp

May 16, 2022

Hygrovest Limited (ASX: HGV) announced that it has agreed to support the proposed changes to the terms of the unsecured convertible debentures, which Entourage Health Corp issued. These proposed changes would allow Hygrovest to divest its investment in Entourage convertible debentures.

The proposed changes by Entourage Health Corp would allow HGV to complete the divestment of Entourage, bringing forward the maturity date from 25 September 2022 to 30 June 2022 and reducing the redemption percentage from 100% to 60% of face value. On the basis that Entourage noteholders approve

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au